Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | PLG | P00747 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8262546 | 1.00 | LMNA (0.65) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL31040391 | 0.94 | LMNA (0.57) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL31040413 | 0.89 | LMNA (0.54) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL31040408 | 0.87 | LMNA (0.52) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL31040447 | 0.87 | LMNA (0.52) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL17530466 | 0.86 | CYP2D6 (0.52) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL20528875 | 0.86 | NFKB1 (0.56) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL2401560 | 0.83 | CYP2D6 (0.44) | LMNATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL28424085 | 0.83 | ACHE (0.49) | KMT2AMEN1ALDH1A1TSHRHDAC3 | |
| Hydrochloric Acid SCHEMBL17373887 | 0.82 | BLM (0.45) | LMNATHRBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20160015656-A2 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | NITTO DENKO CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015656-A2 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | COL1A1, COL2A1, COL14A1 | LMNA 1672/4885THRB 2623/4885KMT2A 4325/4885 |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | KIT, STRA6, HAVCR2 | LMNA 969/4885THRB 975/4885KMT2A 3648/4885 |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | FGFR2, FRS2, FOLR1 | LMNA 3390/4885THRB 3099/4885KMT2A 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.